Compare AAME & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AAME | MDXH |
|---|---|---|
| Founded | 1968 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Life Insurance | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 41.1M |
| IPO Year | 1995 | 2021 |
| Metric | AAME | MDXH |
|---|---|---|
| Price | $1.75 | $0.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 14.8K | ★ 758.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $188,227,000.00 | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | $7.64 | ★ N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $1.59 | $0.45 |
| 52 Week High | $3.71 | $5.33 |
| Indicator | AAME | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 37.67 | 18.95 |
| Support Level | $1.59 | N/A |
| Resistance Level | $3.16 | $3.79 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 43.33 | 11.12 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.